Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PharmaEssentia Corporation
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Vemlidy, Gilead Sciences' follow-on to blockbuster hepatitis B product treatment Viread, has this week won approval in the US and been given the green light for approval in Europe – vital steps in Gilead's long term plan to protect its hep B portfolio from generic erosion.